Celldex Therapeutics (NASDAQ: CLDX) Price Target Soars on Positive Phase III clinical trial results. Sep 23, 2026 Market News FMPCelldex Therapeutics (NASDAQ: CLDX) Price Target Soars on Positive Phase III Cli... * Leerink Partners significantly raised its price target for Celldex Therapeutics to $88.00, indicating strong analyst confidence in the biotechnology stock. * Celldex reported successful Phase III clinical trial results for its drug barzolvolimab in treating chronic spontaneous urticaria (CSU), meeting all primary endpoints. * Despite the positive news regarding CSU, the Celldex stock price experienced a slight decline following the discontinuation of a separate Phase 2 trial for barzolvolimab in another condition. Celldex Therapeutics (NASDAQ: CLDX) is a leading biotechnology stock that develops innovative therapies to treat specific diseases. With a market capitalization of around $2.1 billion, the company focuses on creating targeted treatments through advanced drug development. Its main drug candidate is barzolvolimab, which is being studied for several conditions. On September 23, 2026, Thomas Smith of Leerink Partners increased the price target for Celldex Therapeutics to $88.00 from $70.00. A price target is an analyst's projection of a stock's future price, crucial for stock analysis. At the time, the stock was trading at $31.19, showing significant potential upside according to the analyst. This optimism follows positive results from Celldex's Phase III clinical trials for barzolvolimab. The drug is designed for adults with chronic spontaneous urticaria (CSU), a skin condition, who do not get better with antihistamines. The studies, EMBARQ-CSU1 and EMBARQ-CSU2, met all their main goals, highlighting progress in CSU treatment. The trials showed that barzolvolimab was effective and that its benefits lasted or even improved over 24 weeks. As highlighted by Defense World, these global trials included 1,939 patients. Celldex now plans to submit a Biologics License Application (BLA) in 2027, a key step towards potential FDA approval for the new drug. However, as reported by Benzinga, Celldex also stopped a separate Phase 2 trial of barzolvolimab for a different condition after it failed to meet its goals. Despite the positive CSU news, the Celldex stock price decreased by 6.03% to $31.49 during the day's trading. Market news and analyst rating coverage Andrew Wynn writes market news and analyst-rating coverage for the FMP blog, tracking price-target revisions, broker upgrades and downgrades, and earnings developments across U.S. equities. His posts distill fast-moving market events into clear, factual summaries grounded in financial data. Financial data for every need. Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions - all accessible via API. Stock Screener 2017-2026 (C) FMP

Celldex Therapeutics (NASDAQ:CLDX) given new $50.00 price target at Morgan Stanley. September 10, 2026 Key points. * Morgan Stanley raised its price target for Celldex Therapeutics to $50 from $46 and maintained an "overweight" rating, implying approximately 29.5% upside from the prior close. * Analyst sentiment is broadly positive: Celldex has a consensus "Moderate Buy" rating and an average price target of $56.42, although targets range widely from $42 to $100. * Shares fell 0.4% to $38.62 in Thursday trading. Celldex recently reported a quarterly loss of $0.94 per share, which was better than the expected $1.06 loss, but revenue of $0.02 million came in below expectations. * Five stocks we like better than Celldex Therapeutics. Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) had its target price lifted by Morgan Stanley from $46.00 to $50.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an "overweight" rating on the biopharmaceutical company's stock. Morgan Stanley's price target points to a potential upside of 29.48% from the company's previous close. Several other analysts have also recently weighed in on the stock. Wall Street Zen raised shares of Celldex Therapeutics from a "strong sell" rating to a "sell" rating in a report on Sunday, July 12th. HC Wainwright reiterated a "buy" rating and set a $42.00 price target on shares of Celldex Therapeutics in a report on Monday, June 15th. Cantor Fitzgerald dropped their price objective on shares of Celldex Therapeutics from $67.00 to $61.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 22nd. Guggenheim raised their price objective on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a "buy" rating in a report on Monday, July 20th. Finally, UBS Group lifted their price objective on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a "buy" rating in a research report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Celldex Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $56.42. Celldex Therapeutics trading down 0.4%. NASDAQ:CLDX traded down $0.17 during midday trading on Thursday, reaching $38.62. The company had a trading volume of 221,694 shares, compared to its average volume of 931,862. Celldex Therapeutics has a 12-month low of $22.10 and a 12-month high of $45.14. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of -8.88 and a beta of 0.84. The stock's fifty day simple moving average is $39.19 and its 200-day simple moving average is $34.22. Discover more Stock split calculator Stock profit calculator Stock market news Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.12. The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.73 million. As a group, sell-side analysts expect that Celldex Therapeutics will post -4.17 EPS for the current year. Hedge funds weigh in on Celldex Therapeutics. Hedge funds have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB acquired a new position in shares of Celldex Therapeutics in the 3rd quarter valued at $42,000. Russell Investments Group Ltd. raised its stake in Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 501 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Celldex Therapeutics during the 3rd quarter worth $63,000. Nykredit A S purchased a new stake in Celldex Therapeutics in the second quarter valued at $67,000. Finally, Kestra Advisory Services LLC acquired a new position in Celldex Therapeutics in the fourth quarter valued at $98,000. Celldex Therapeutics company profile. Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company's research platforms leverage novel antibody and vaccine technologies designed to engage the patient's immune system, with a particular emphasis on oncology and neurologic indications. Celldex's pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity. Among Celldex's lead product candidates is glembatumumab vedotin, an antibody-drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Celldex Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list. While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow. Continue following MarketBeat

Celldex to present at upcoming Investor Conference. HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) - Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET. The webcast of the presentation will be available on the "Events and Presentations" page of the "Investors" section of the Celldex Website. Replays will be available for 90 days following the event. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com. Company Contacts Sarah Cavanaugh Senior Vice President, Corporate Affairs & Administration (508) 864-8337 [email protected] Elizabeth Higgins Executive Director, Investor Relations & Corporate Communications (857) 404-2088 [email protected]